NATIXIS ADVISORS, LLC

Position in ALNY — Alnylam Pharmaceuticals, Inc.

CIK 1018331 Boston, MA

Position in ALNY

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$25,813,153

+$8,183,341 QoQ

Shares Held

78,016

+76.0% QoQ

Ownership

0.059%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2021

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

NATIXIS ADVISORS, LLC holds $475,548,112 across 32 Biotechnology names. ALNY ranks #4 (5.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	554,024	$247,393,876
2	REGN	Regeneron Pharmaceuticals, Inc.	125,673	$97,099,986
3	TECH	BIO-TECHNE Corp	648,034	$33,866,256
4	ALNY	Alnylam Pharmaceuticals, Inc. This page	78,016	$25,813,153
5	ARGX	Argenx SE	20,380	$14,882,495
6	INSM	INSMED Inc	42,934	$7,020,567
7	HALO	Halozyme Therapeutics, Inc.	106,305	$6,870,492
8	JAZZ	Jazz Pharmaceuticals plc	26,729	$5,053,117

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$25,813,153	78,016	+76.0%	Shares	Defined	2026-05-13
2025-12-31	$17,629,812	44,335	+104.5%	Shares	Defined	2026-02-10
2025-09-30	$9,886,992	21,682	+114.5%	Shares	Defined	2025-11-13
2025-06-30	$3,296,443	10,109	-3.3%	Shares	Defined	2025-08-13
2024-12-31	$2,459,695	10,453	+4.5%	Shares	Defined	2025-02-10
2024-09-30	$2,750,850	10,002	-3.4%	Shares	Defined	2024-11-06
2022-03-31	$1,691,521	10,359	-17.3%	Shares	Defined	2022-05-12
2021-12-31	$2,123,650	12,523	-36.9%	Shares	Defined	2022-02-08
2021-09-30	$3,748,256	19,852	+74.3%	Shares	Defined	2021-11-15
2021-06-30	$1,931,002	11,391	—	Shares	Defined	2021-08-12
No filing history on record for this holder in this stock.